We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+10.59%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$998M
AUM Growth
+$20.9M
Cap. Flow
-$63M
Cap. Flow %
-6.31%
Top 10 Hldgs %
28.11%
Holding
91
New
2
Increased
24
Reduced
43
Closed
3

Top Buys

Rank Stock Value
1
DPLO
DIPLOMAT PHARMACY, INC.
DPLO
+$22M
2
CI icon
Cigna
CI
+$8.21M
3
AERI
Aerie Pharmaceuticals
AERI
+$7.07M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$6.46M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$6.29M

Top Sells

Rank Stock Value
1
ESRX
Express Scripts Holding Company
ESRX
+$22.8M
2
NKTR icon
Nektar Therapeutics
NKTR
+$17.8M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$13.6M
4
WBA
Walgreens Boots Alliance
WBA
+$12.6M
5
LOXO
Loxo Oncology, Inc
LOXO
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 91.36%
2 Financials 1.12%
3 Technology 0.14%
4 Energy 0.14%
5 Communication Services 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CI icon
1
Cigna
CI
$73.7B
$36.4M 3.65%
174,691
+44,291
+34% +$8.21M
CVS icon
2
CVS Health
CVS
$133B
$34.5M 3.46%
438,868
+65,000
+17% +$4.65M
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
$33.8M 3.39%
243,329
+51,466
+27% +$6.46M
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$121B
$27.5M 2.75%
142,465
-12,535
-8% -$2.23M
INCY icon
5
Incyte
INCY
$24.2B
$26M 2.61%
376,916
-6,847
-2% -$470K
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$11.6B
$25.7M 2.57%
264,849
+25,000
+10% +$2.5M
ABMD
7
DELISTED
Abiomed Inc
ABMD
$25.1M 2.51%
55,701
-4,699
-8% -$1.85M
MDT icon
8
Medtronic
MDT
$109B
$24.6M 2.46%
249,874
-30,000
-11% -$2.77M
UNH icon
9
UnitedHealth
UNH
$376B
$24.2M 2.43%
91,000
-5,000
-5% -$1.3M
DPLO
10
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$22.8M 2.28%
1,174,411
+1,032,047
+725% +$22M
EXEL icon
11
Exelixis
EXEL
$13.3B
$22.4M 2.24%
1,261,414
+320,200
+34% +$6.24M
JAZZ icon
12
Jazz Pharmaceuticals
JAZZ
$15.9B
$21.2M 2.13%
126,322
-2,114
-2% -$364K
NVCR icon
13
NovoCure
NVCR
$1.73B
$21M 2.1%
400,000
-50,000
-11% -$1.99M
BDX icon
14
Becton Dickinson
BDX
$45.6B
$20.9M 2.09%
82,000
-5,125
-6% -$1.26M
BMY icon
15
Bristol-Myers Squibb
BMY
$133B
$20.5M 2.05%
330,000
-110,000
-25% -$6.53M
SGMO
16
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$20.3M 2.03%
1,197,357
+145,424
+14% +$2.21M
ABT icon
17
Abbott
ABT
$183B
$19.4M 1.94%
264,552
+52,552
+25% +$3.45M
ELV icon
18
Elevance Health
ELV
$81.5B
$19.2M 1.92%
70,000
-6,000
-8% -$1.56M
NKTR icon
19
Nektar Therapeutics
NKTR
$2.39B
$18.6M 1.87%
20,360
-20,817
-51% -$17.8M
GKOS icon
20
Glaukos
GKOS
$9.83B
$18.3M 1.83%
281,279
-78,721
-22% -$3.86M
LLY icon
21
Eli Lilly
LLY
$1.02T
$18.2M 1.83%
170,000
-30,000
-15% -$3M
HZNP
22
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$18M 1.8%
917,051
-715,161
-44% -$13.6M
HUM icon
23
Humana
HUM
$43.7B
$17.9M 1.8%
53,000
-20,000
-27% -$6.5M
SAGE
24
DELISTED
Sage Therapeutics
SAGE
$17.6M 1.77%
124,739
-4,940
-4% -$763K
ARNA
25
DELISTED
Arena Pharmaceuticals Inc
ARNA
$16.9M 1.69%
366,387
+81,766
+29% +$3.31M
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2018 Portfolio in Review

As of Q3 2018, Rhenman & Partners Asset Management held 91 positions worth $998M, up 2.1% from $977M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $63M in Q3 2018, closing 3 positions and reducing 43 holdings. Its most notable exit was Express Scripts Holding Company, an estimated $22.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Financials and Technology.

Against the trend, Rhenman & Partners Asset Management opened a new position in Pediatrix Medical worth $5.82M.

  • Rhenman & Partners Asset Management's largest Q3 2018 buy was Pediatrix Medical: 124,674 shares worth $5.82M.
  • Rhenman & Partners Asset Management added most to DIPLOMAT PHARMACY, INC. in Q3 2018, an estimated $22M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2018 reduction was Nektar Therapeutics, cutting an estimated $17.8M.
  • Rhenman & Partners Asset Management fully exited Express Scripts Holding Company in Q3 2018, selling an estimated $22.8M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 28% of its $998M portfolio in Q3 2018.
  • Rhenman & Partners Asset Management opened 2 new positions and closed 3 in Q3 2018.
  • Rhenman & Partners Asset Management's portfolio value rose 2.1% quarter-over-quarter to $998M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2018, filed 3 Oct 2018.